Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple myeloma (RRMM). In 21-day cycles, patients receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, P G, Hofmeister, C C, Raje, N S, Siegel, D S, Lonial, S, Laubach, J, Efebera, Y A, Vesole, D H, Nooka, A K, Rosenblatt, J, Doss, D, Zaki, M H, Bensmaine, A, Herring, J, Li, Y, Watkins, L, Chen, M S, Anderson, K C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729338/
https://www.ncbi.nlm.nih.gov/pubmed/28642620
http://dx.doi.org/10.1038/leu.2017.173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729338/
https://www.ncbi.nlm.nih.gov/pubmed/28642620
http://dx.doi.org/10.1038/leu.2017.173

Ejemplares similares